Comparative Pharmacology
Head-to-head clinical analysis: AMANTADINE HYDROCHLORIDE versus INBRIJA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMANTADINE HYDROCHLORIDE versus INBRIJA.
AMANTADINE HYDROCHLORIDE vs INBRIJA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amantadine hydrochloride is an antiviral and antiparkinsonian agent. Its antiviral mechanism involves inhibition of the M2 ion channel of influenza A virus, preventing viral uncoating and replication. In Parkinson's disease, it increases dopamine release and inhibits dopamine reuptake, and also acts as an NMDA glutamate receptor antagonist, reducing excitotoxicity.
INBRIJA (levodopa inhalation powder) is a combination of levodopa, an aromatic amino acid, and a prodrug of dopamine, which is decarboxylated to dopamine in the brain, thereby restoring dopamine levels in the striatum and improving motor function in Parkinson disease.
For parkinsonism/drug-induced extrapyramidal symptoms: initial 100 mg twice daily; may increase to 300-400 mg/day in divided doses if needed. For influenza A treatment/prophylaxis in adults: 200 mg once daily or 100 mg twice daily; initiate prophylaxis as early as possible and continue for at least 10 days post-exposure.
Inhaled levodopa powder, 84 mg (two 42 mg capsules) inhaled orally via the INBRIJA inhaler as needed for OFF episodes, up to 5 times per day. Maximum daily dose: 420 mg (5 doses).
None Documented
None Documented
Terminal elimination half-life: 10-14 hours in young adults; up to 34 hours in elderly (due to age-related decline in renal function); prolonged in renal impairment (up to 7 days in anuria).
0.75–1.5 hours (terminal elimination half-life of levodopa). Short half-life necessitates frequent dosing or continuous dopaminergic stimulation strategies.
Renal: 90% unchanged drug via glomerular filtration and tubular secretion; minor fecal (<5%) and biliary elimination.
Primarily renal excretion of metabolites and unchanged drug. Approximately 80% of a dose is recovered in urine as levodopa metabolites (mainly 3-O-methyldopa and vanilpyruvic acid) and <10% as unchanged levodopa. Fecal excretion accounts for <5%.
Category C
Category C
Antiviral / Antiparkinsonian
Antiparkinsonian